{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000091","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.735084+00:00","generated_at":"2026-05-17T15:33:30.119917+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year","bullets":["Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).","Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.","Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.","Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.","Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000091","json":"https://secwatch.observer/filing/0001708599-25-000091.json","markdown":"https://secwatch.observer/filing/0001708599-25-000091.md","text":"https://secwatch.observer/filing/0001708599-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/0001708599-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/ser-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:33:30.119917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}